1.A clinical study of childhood soft tissue sarcoma.
Hye Lim JUNG ; Hong Heo KOO ; Hee Young SHIN ; Hyo Seop AHN
Journal of the Korean Pediatric Society 1993;36(9):1258-1270
To study the clinical characteristics and treatment results of childhood soft tissue sarcoma, the retrospective study was performed on 67 patients with soft tissue sarcoma, experienced at the Department of Pediatrics, Seoul National University Hospital from January, 1982 to July, 1990. The median age of 67 soft tissue sarcoma patients was 4 years 5 months and age distribution showed that 0-4 year age group was most common (55.2%). The sex ratio of male to female was 1.2:1. There were 3 cancers among relatives of soft tissue sarcoma patients, including one cancer among first-degree relatives. As for pathological classification, rhabdomyosarcoma (67.1%) was the most common childhood soft tissue sarcoma, followed by malignant Schwannoma (8.9%), extraskeletal Ewing's sarcoma (6.0%), infantile fibrosarcoma (4.5%), malignant fibrous histiocytoma (3.0%), malignant hemangiopericytoma (3.0%), and there were 1 case each of angiosarcoma, leiomyosarcoma, synovial sarcoma, malignant mesenchymoma and mesenchymal chondrosarcoma. The median age of 45 rhabdomyosarcoma patients was 3 years 8 months and age distribution showed that 0-4 year age group was most common (64.5%). Twenty three patients were male and 22 were female. The histologic subtype of rhabdomyosarcoma was embryonal type in 38 patients (84.5%), alveolar type in 5 patients (11.1%) and unclassified type in 2 patients (4.4%). As for primary site of soft tissue sarcomas, the most frequent site was the head and neck region (32.8%) including parameningeal region (13.4%) and orbit (6.0%), followed by extremities (20.9%), trunk (19.4%), retroperitoneum and pelvis (11.9%), urogenital region (7.5%), perineum and perianal region (4.5%) and other region (3.0%). As for primary site of 45 rhabdomyosarcoma cases, the most frequent site was also the head and neck region (37.8%). The most common initial symptom of soft tissue sarcoma patients was mass (68.7%). As for Intergroup Rhabdomyosarcoma Study clinical grouping system of 67 soft tissue sarcoma patients, clinical group III (58.2%) was most common, followed by clinical group II(20.9%), IV (14.9%) and I (6.0%). Of 10 cases of clinical group IV with distant metastasis, lung (8 cases) was the most common metastaic region and other metastatic regions were bone, kidney, liver and bone marrow. As for IRS clinical grouping system of 45 rhabdomyosarcoma patients, clinical group III was most common (68.9%). Of 6 cases of clinical group IV, lung (5 cases) was also the most common metastatic region, followed by kidney and liver. From 1982 to 1985, chemotherapy was done with pulse VAC or pulse VAdrC-VAC regimen based on IRS-I and IRS-II. From 1986, patients in clinical group I and II received vincristine and actinomycin-D for 1 year and patients in clinical group III, IV and II with alveolar histologic subtype(unfavorable histologic group) received vincristine, actinomycin-D, adriamycin, cyclophosphamide and cisplatinum based on IRS-III. Radiation therapy was administered to patients in clinical group II, III and IV. Of 67 cases of soft tissue sarcoma, 54 case were eligible for treatment analysis. The 3 year disease free survival (DFS) of all 54 cases was 54.1%, 3 year DFS of clinical group I and II was 83.9%,3 year DFS of clinical group III and IV before 1986 was 35.7% and after 1986 was 48.2%. Of 45 cases of rhabdomyosarcoma, 41 cases were eligible for treatment analysis. The 3 year DFS of all 41 cases was 49.1%,3 year DFS of clinical group I and II was 87.5%,3 year DFS of clinical group III and IV before 1986 was 27.2% and after 1986 was 45.0%. Patients in clinical group I and II who had no gross residual tumor after primary surgical excision had best prognosis with 3 year DFS approximating 90% with only 2 drugs regimen, significantly better than patients in clinical group III and IV with 3 year DFS below 50% even after intensifying chemotherapy since year 1986. This analysis suggests that total surgical removal is very important for improving prognosis and should be undertaken where possible in all patients without distant metastasis. Treatment results also showed that after year 1986 with intensification of chemotherapy, 3 year DFS of clinical group III and IV as well as early toxic deaths increased, and after lowering doses of chemotherapeutic agents of regimen 35 of IRS-III, treatment results improved much. Therfore to improve prognosis of patients with gross residual tumor after surgical excision of biopsy and patients with distant metastasis at diagnosis, intensified multiagent chemcherapeutic regimen with adequate dose modification should be done to lower early toxic deaths.
Age Distribution
;
Biopsy
;
Bone Marrow
;
Chondrosarcoma, Mesenchymal
;
Classification
;
Cyclophosphamide
;
Diagnosis
;
Disease-Free Survival
;
Doxorubicin
;
Drug Therapy
;
Extremities
;
Female
;
Fibrosarcoma
;
Head
;
Hemangiopericytoma
;
Hemangiosarcoma
;
Histiocytoma, Malignant Fibrous
;
Humans
;
Kidney
;
Leiomyosarcoma
;
Liver
;
Lung
;
Male
;
Mesenchymoma
;
Neck
;
Neoplasm Metastasis
;
Neoplasm, Residual
;
Neurilemmoma
;
Orbit
;
Pediatrics
;
Pelvis
;
Perineum
;
Prognosis
;
Retrospective Studies
;
Rhabdomyosarcoma
;
Sarcoma*
;
Sarcoma, Ewing
;
Sarcoma, Synovial
;
Seoul
;
Sex Ratio
;
Survival Rate
;
Vincristine
2.New Oral Anticoagulants May Be Particularly Useful for Asian Stroke Patients.
Oh Young BANG ; Keun Sik HONG ; Ji Hoe HEO ; Jaseong KOO ; Sun U KWON ; Kyung Ho YU ; Hee Joon BAE ; Byung Chul LEE ; Byung Woo YOON ; Jong S KIM
Journal of Stroke 2014;16(2):73-80
Atrial fibrillation (AF) is an emerging epidemic in both high-income and low-income countries, mainly because of global population aging. Stroke is a major complication of AF, and AF-related ischemic stroke is more disabling and more fatal than other types of ischemic stroke. However, because of concerns about bleeding complications, particularly intracranial hemorrhage, and the limitations of a narrow therapeutic window, warfarin is underused. Four large phase III randomized controlled trials in patients with non-valvular AF (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) demonstrated that new oral anticoagulants (NOACs) are superior or non-inferior to warfarin as regards their efficacy in preventing ischemic stroke and systemic embolism, and superior to warfarin in terms of intracranial hemorrhage. Among AF patients receiving warfarin, Asians compared to non-Asians are at higher risk of stroke or systemic embolism and are also more prone to develop major bleeding complications, including intracranial hemorrhage. The extra benefit offered by NOACs over warfarin appears to be greater in Asians than in non-Asians. In addition, Asians are less compliant, partly because of the frequent use of herbal remedies. Therefore, NOACs compared to warfarin may be safer and more useful in Asians than in non-Asians, especially in stroke patients. Although the use of NOACs in AF patients is rapidly increasing, guidelines for the insurance reimbursement of NOACs have not been resolved, partly because of insufficient understanding of the benefit of NOACs and partly because of cost concerns. The cost-effectiveness of NOACs has been well demonstrated in the healthcare settings of developed countries, and its magnitude would vary depending on population characteristics as well as treatment cost. Therefore, academic societies and regulatory authorities should work together to formulate a scientific healthcare policy that will effectively reduce the burden of AF-related stroke in this rapidly aging society.
Aging
;
Anticoagulants*
;
Asian Continental Ancestry Group*
;
Atrial Fibrillation
;
Delivery of Health Care
;
Developed Countries
;
Embolism
;
Health Care Costs
;
Hemorrhage
;
Humans
;
Insurance
;
Intracranial Hemorrhages
;
Population Characteristics
;
Stroke*
;
Warfarin
3.The Reliability and Validity of Korean QOLIE-31 in Patients with Epilepsy.
Hee Jung YOO ; Sang Ahm LEE ; Kyoung HEO ; Joong Koo KANG ; Ryeo Won KO ; Sang Do YI ; Ju Hwa LEE ; Seung Bong HONG ; Jae Moon KIM ; Byung In LEE
Journal of Korean Epilepsy Society 2002;6(1):45-52
BACKGROUND: To develop a Korean version of the QOLIE-31 and to confirm its psychometric properties. METHODS: The QOLIE-31 was adapted to Korean language through a translation-back translation procedure. Data were collected from 397 adult epilepsy patients. Patients were administered the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), Korean Wechsler Intelligence Scale (KWIS), the Functional Assessment of Cancer Therapy-General (FACT-G), state scale of the State-Trait Anxiety Inventory (STAI), and the Center for Epidemiological Studies-Depression Scale (CES-D). We assessed internal consistency and test-retest reliabilities and construct validity. RESULTS: Cronbach's alpha ranged from 0.69 to 0.86, and test-retest reliability was between 0.50 and 0.71, demonstrating that the items of OOLIE-31 are internally consistent and temporally stable. Pearson's correlations among the QOLIE-31 and emotional well-being, state anxiety, and depressive symptoms were high. Most QOLIE-31 sub-scales discriminated well between patients according to seizure frequency, number of antiepileptic drugs, employment, economic status and depressive symptoms. CONCLUSION: The Korean version of the QOLIE-31 was reliable, and showed construct validity comparable with the original U.S version. Results confirmed that the QOLIE-31 can be applied as one of the specific measures of quality of life in Korean epilepsy patients.
Adult
;
Anticonvulsants
;
Anxiety
;
Depression
;
Employment
;
Epilepsy*
;
Humans
;
Intelligence
;
Psychometrics
;
Quality of Life
;
Reproducibility of Results*
;
Seizures
4.Cyclooxygenase-2 Expression in Intrahepatic Cholangiocarcinoma.
Koo Yong HAHN ; Seong Woo HONG ; Yun Kyung KANG ; Tae Gil HEO ; Yeo Goo CHANG ; In Wook PAIK ; Hyucksang LEE
Korean Journal of Hepato-Biliary-Pancreatic Surgery 2003;7(1):102-107
BACKGROUND/AIMS: Cyclooxygenase (COX)-2 levels are elevated in several types of human cancer tissues. COX-2 is not constitutively expressed by most normal tissues, but it is rapidly induced by certain inflammatory cytokines, tumor promoters, growth factors and oncogenes. Inflammation is important risk factor for intrahepatic cholangiocarcinoma. Therefore, this study was aimed to evaluate the role of COX-2 in intrahepatic cholangiocarcinoma development. METHODS: 18 intrahepatic cholangiocarcinoma patients was conducted in this study. COX-2 expression was investigated by immunohistochemical staining in resected liver specimen that involved 47 hyperplasia, 30 low-grade dysplasia, 38 high- grade dysplasia and 18 cancer. The relationship of clinicopathological factor and COX-2 expression of cancer was evaluated. RESULTS: COX-2 expression was not observed in normal bile duct epithelium. COX-2 expression in high-gade dysplasia was higher than in low-grade dysplasia. COX-2 expression in cancer was higher than in hyperplasia, low-grade and high grade dysplasia. There was no significant correlation between clinicopathological factors and COX-2 expression in cancer. CONCLUSION: These findings suggest that COX-2 may play a role in the early and late carcinogensis of intrahepatic cholangiocarcinoma.
Bile Ducts
;
Carcinogenesis
;
Carcinogens
;
Cholangiocarcinoma*
;
Cyclooxygenase 2*
;
Cytokines
;
Epithelium
;
Humans
;
Hyperplasia
;
Inflammation
;
Intercellular Signaling Peptides and Proteins
;
Liver
;
Oncogenes
;
Prostaglandin-Endoperoxide Synthases
;
Risk Factors
5.Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy.
Ji Eun HEO ; Kyo Chul KOO ; Sung Joon HONG ; Sang Un PARK ; Byung Ha CHUNG ; Kwang Suk LEE
Yonsei Medical Journal 2018;59(2):219-225
PURPOSE: To evaluate parameters for determining repeat prostate biopsy in patients with 5α-reductase inhibitor (5ARI) treatment after initial negative biopsy. MATERIALS AND METHODS: From January 2007 to December 2015, patients who underwent a repeat prostate biopsy after an initial negative biopsy were enrolled from multiple institutions. Serial prostate-specific antigen (PSA) levels after the initial biopsy were analyzed for PSA kinetics. Clinicopathologic variables were evaluated according to the use of 5ARIs after the initial negative biopsy. RESULTS: Of 419 patients with initial negative biopsies (median age=67.0 years, median PSA=6.31 ng/mL), 101 patients (24.1%) were diagnosed with prostate cancer at the repeat biopsy. An increase in PSA level at 18 months, compared to that at 6 months, was a predictor of a positive repeat biopsy. However, the use of 5ARIs was not identified as a predictor. Of 126 patients receiving 5ARI treatment after the initial biopsy, 30 (23.8%) were diagnosed with prostate cancer at the repeat biopsy. Increase in PSA level at more than two time points after 6 months of 5ARI treatment (odds ratio=4.84, p=0.005) was associated with cancer detection at the repeat biopsy. There were no significant 5ARI group-related differences in the detection rates of prostate and high-grade cancers (Gleason score ≥7). CONCLUSION: The effects of 5ARIs on prostate cancer detection and chemoprevention remain uncertain. However, more than two increases in PSA level after 6 months of 5ARI treatment may indicate the presence of prostate cancer.
5-alpha Reductase Inhibitors/*therapeutic use
;
Aged
;
*Biopsy
;
Follow-Up Studies
;
Humans
;
Kinetics
;
Male
;
Middle Aged
;
Neoplasm Grading
;
Predictive Value of Tests
;
Prostate-Specific Antigen/*blood
;
Prostatic Neoplasms/blood/*drug therapy/*pathology
6.Effect of Epitympanoplasty with Mastoid Obliteration Technique on Postoperative Rehabilitation of Hearing Impaired.
Myung Koo KANG ; Sung Hwa HONG ; Sung Hyun BOO ; Woo Yong BAE ; Chang Gun KIM ; Dong Young KIM ; Heon Soo PARK ; Seong Duk HEO
Korean Journal of Otolaryngology - Head and Neck Surgery 2002;45(8):755-759
BACKGROUND AND OBJECTIVES: This study was designed to identify whether canal type hearing aids can be used by the patients who have undergone epitympanoplasty with mastoid obliteration for postoperative rehabilitation of hearing impaired and also to investigate the advantages of the complete in the canal (CIC) hearing aid for the postoperative rehabilitation of hearing impaired. SUBJECTS AND METHOD: Fourty-three ears belonging to 40 adults, who were treated by epitympanoplasty with mastoid obliteration for cholesteatoma from April 1995 to May 1999 were involved in this study. The impressions were taken and measured postoperatively by Vernier calipers anteroposteriorly (AP) and superoinferiorly (SI). It is well known that the size of the external auditory canal (EAC) should be over 7 mm in diameter and over 2 cm in length to be able to wear the CIC type hearing aid. The shape of the EAC was also taken into consideration. RESULTS: Thirty-five out of 43 ears were large enough to wear CIC hearing aids and all 43 for the canal (ITC) hearing aids. No ears were excluded from being able to wear a CIC or ITC hearing aid with respect to the shape of the EAC. CONCLUSION: Canal type hearing aides can be used after epitympanoplasty with mastoid obliteration which is used as a treatment of cholesteatoma.
Adult
;
Cholesteatoma
;
Correction of Hearing Impairment*
;
Ear
;
Ear Canal
;
Hearing Aids
;
Humans
;
Mastoid*
;
Rehabilitation*
7.Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
Keun-Sik HONG ; Oh Young BANG ; Jong-Ho PARK ; Jin-Man JUNG ; Sang-Hun LEE ; Tae-Jin SONG ; Hyo Suk NAM ; Hee-Kwon PARK ; Keun-Hwa JUNG ; Sung Hyuk HEO ; Jaseong KOO ; Kyung-Ho YU ; Kwang-Yeol PARK ; Chi Kyung KIM ; Hong-Kyun PARK ; Jiyoon LEE ; Juneyoung LEE ; Woo-Keun SEO
Journal of Stroke 2023;25(2):242-250
Background:
and Purpose Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke.
Methods:
This randomized, open-label, controlled trial assigned patients with recent ischemic stroke <90 days to rosuvastatin/ezetimibe 10/10 mg once daily (ROS10/EZT10) or to rosuvastatin 20 mg once daily (ROS20). The primary endpoint was LDL-C reduction ≥50% from baseline at 90 days. Key secondary endpoints were LDL-C <70 mg/dL and multiple lipid goal achievement, and composite of major vascular events.
Results:
Of 584 randomized, 530 were included in the modified intention-to-treat analysis. The baseline LDL-C level was 130.2±34.7 mg/dL in the ROS10/EZT10 group and 131.0±33.9 mg/dL in the ROS20 group. The primary endpoint was achieved in 198 patients (72.5%) in the ROS10/EZT10 group and 148 (57.6%) in the ROS20 group (odds ratio [95% confidence interval], 1.944 [1.352–2.795]; P= 0.0003). LDL-C level <70 mg/dL was achieved in 80.2% and 65.4% in the ROS10/EZT10 and ROS20 groups (P=0.0001). Multiple lipid goal achievement rate was 71.1% and 53.7% in the ROS10/EZT10 and ROS20 groups (P<0.0001). Major vascular events occurred in 1 patient in the ROS10/EZT10 group and 9 in the ROS20 group (P=0.0091). The adverse event rates did not differ between the two groups.
Conclusion
Moderate-intensity rosuvastatin plus ezetimibe was superior to high-intensity rosuvastatin alone for intensive LDL-C reduction in patients with recent ischemic stroke. With the combination therapy, more than 70% of patients achieved LDL-C reduction ≥50% and 80% had an LDL-C <70 mg/dL at 90 days.
8.Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer.
Tae Ryool KOO ; Hong Gyun WU ; J Hun HAH ; Myung Whun SUNG ; Kwang Hyun KIM ; Bhumsuk KEAM ; Tae Min KIM ; Se Hoon LEE ; Dong Wan KIM ; Dae Seog HEO ; Charn Il PARK
Cancer Research and Treatment 2012;44(4):227-234
PURPOSE: The purpose of this study is to analyze treatment outcome of radiotherapy (RT) in patients with stage III-IV tonsil cancer managed by surgery followed by postoperative RT (SRT) and definitive chemoradiotherapy (CRT), and to thereby evaluate the most feasible treatment modality. MATERIALS AND METHODS: Of 124 patients, 67 underwent CRT, and 57 underwent SRT. We compared survival and complication rates in both groups. RESULTS: The median follow-up time was 57 months (range, 19 to 255 months) for surviving patients. At five years, locoregional progression-free survival (LRPFS) and overall survival (OS) were 88% and 80%, respectively. No significant difference in LRPFS (p=0.491) and OS (p=0.177) was observed between CRT and SRT. In multivariate analysis, old age and higher T stage showed a significant association with poor LRPFS, PFS, and OS; higher N stage showed an association with poor PFS and a trend of poor LRPFS, while no association with OS was observed; treatment modality (CRT and SRT) showed no association with LRFPS, PFS, and OS. Grade 3 or higher mucositis was observed in 12 patients (21%) in the SRT group, and 25 patients (37%) in the CRT group. CONCLUSION: Definitive CRT and SRT have similar treatment outcomes for patients with stage III-IV tonsil cancer. Although acute complication rate appears to be higher in the CRT group, it should be noted that not all data on complications were included in this retrospective study. To determine the most feasible treatment modality, not only mucositis and xerostomia, but also emotional aspect and quality of life, should be considered.
Chemoradiotherapy
;
Disease-Free Survival
;
Follow-Up Studies
;
Humans
;
Mucositis
;
Multivariate Analysis
;
Palatine Tonsil
;
Quality of Life
;
Radiotherapy, Intensity-Modulated
;
Retrospective Studies
;
Tonsillar Neoplasms
;
Treatment Outcome
;
Xerostomia
9.Clinical Features and Prognosis of Spontaneous Bacterial Peritonitis in Korean Patients with Liver Cirrhosis: A Multicenter Retrospective Study.
Jeong HEO ; Yeon Seok SEO ; Hyung Joon YIM ; Taeho HAHN ; Sang Hoon PARK ; Sang Hoon AHN ; Jun Yong PARK ; Ji Young PARK ; Moon Young KIM ; Sung Keun PARK ; Mong CHO ; Soon Ho UM ; Kwang Hyub HAN ; Hong Soo KIM ; Soon Koo BAIK ; Byung Ik KIM ; Se Hyun CHO
Gut and Liver 2009;3(3):197-204
BACKGROUND/AIMS: Although early recognition and treatment with effective antibiotics have lead to improvements in the prognosis of patients with spontaneous bacterial peritonitis (SBP), it remains to be a serious complication in cirrhotic patients. This study was designed to evaluate the clinical manifestations and prognosis of patients with liver cirrhosis and SBP in Korea. METHODS: This was a multicenter retrospective study examining 157 episodes of SBP in 145 patients with cirrhosis. SBP was diagnosed based on a polymorphonuclear cell count in ascitic fluid of >250 cells/mm3 in the absence of data compatible with secondary peritonitis. RESULTS: The mean age of the cohort was 56 years, and 121 (77%) of the 157 episodes of SBP occurred in men. Microorganisms were isolated in 66 episodes (42%): Gram-negative bacteria in 54 (81.8%), Gram-positive in 11 (16.7%), and Candida in 1. Isolated Gram-negative organisms were resistant to third-generation cephalosporin in 6 cases (17%), to ciprofloxacin in 11 (20.8%), and to penicillin in 33 (62.3%). The treatment failure and in-hospital mortality rates were 12.1% and 21%, respectively. A high Model of End-Stage Liver Disease (MELD) score, SBP caused by extended-spectrum beta-lactamase-producing organisms, and hepatocellular carcinoma were independent prognostic factors of high in-hospital mortality. CONCLUSIONS: SBP remains to be a serious complication with high in-hospital mortality, especially in patients with a high MELD score.
Anti-Bacterial Agents
;
Ascitic Fluid
;
Candida
;
Carcinoma, Hepatocellular
;
Cell Count
;
Ciprofloxacin
;
Cohort Studies
;
Fibrosis
;
Gram-Negative Bacteria
;
Hospital Mortality
;
Humans
;
Liver
;
Liver Cirrhosis
;
Liver Diseases
;
Male
;
Penicillins
;
Peritonitis
;
Prognosis
;
Retrospective Studies
;
Treatment Failure
10.Management of Asymptomatic Carotid Stenosis for Primary Stroke Prevention: 2012 Focused Update of Korean Clinical Practice Guidelines for Stroke.
Hahn Young KIM ; Seong Rim KIM ; Pyoung JEON ; Hyun Seung KANG ; Kyusik KANG ; Jaseong KOO ; Jong Moo PARK ; Yong Jin CHO ; Sang Won HAN ; Kyung Ho YU ; Joung Ho RHA ; Ji Hoe HEO ; Sun Uck KWON ; Chang Wan OH ; Hee Joon BAE ; Byung Chul LEE ; Byung Woo YOON ; Keun Sik HONG
Journal of the Korean Neurological Association 2012;30(2):77-87
Extracranial carotid stenosis is a well-established, modifiable risk factor for stroke. Asymptomatic extracranial carotid stenosis is increasingly being detected due to the introduction of less-invasive and more-sensitive advanced diagnostic technologies. For severe asymptomatic stenosis, earlier pivotal clinical trials demonstrated the benefit of carotid endarterectomy over the best medical therapy. Since then, great advances have been made in interventional and medical therapies as well as surgical techniques. The first edition of the Korean Stroke Clinical Practice Guidelines for primary stroke prevention for the management of asymptomatic carotid stenosis reflected evidences published before June 2007. After the publication of the first edition, several major clinical trials and observational studies have been published, and major guidelines updated their recommendation. Accordingly, the writing group of Korean Stroke Clinical Practice Guidelines (CPG) decided to provide timely updated evidence-based recommendations. The Korean Stroke CPG writing committee has searched and reviewed literatures related to the management of asymptomatic carotid stenosis including published guidelines, meta-analyses, randomized clinical trials, and nonrandomized studies published between June 2007 and Feb 2011. We summarized the new evidences and revised our recommendations. Key changes in the updated guidelines are the benefit of intensive medical therapy and further evidence of carotid artery stenting as an alternative to carotid endarterectomy. The current updated guidelines underwent extensive peer review by experts from the Korean Stroke Society, Korean Society of Intravascular Neurosurgery, Korean Society of Interventional Neuroradiology, Korean Society of Cerebrovascular Surgery, and Korean Neurological Association. New evidences will be continuously reflected in future updated guidelines.
Carotid Arteries
;
Carotid Stenosis
;
Constriction, Pathologic
;
Endarterectomy, Carotid
;
Neurosurgery
;
Peer Review
;
Primary Prevention
;
Publications
;
Risk Factors
;
Stents
;
Stroke
;
Writing